A Pan-Cancer Analysis of Clinical Prognosis and Immune Infiltration of CKS1B in Human Tumors

Figure 3

Expression levels of CKS1B in LAML and GEM tissue specimens. (a) RNA sequencing results in LAML showed CKS1B was not among the top 50 differentially expressed genes in the remission (CR) and nonremission (NR) groups after chemotherapy. Although specific data indicated CKS1B was higher in the NR group than that of the CR group (63.5 vs. 57.42), the results showed no statistical difference. (b) RT-qPCR results in GEM showed CKS1B mRNA in patients with good DFS was higher than that in patients with bad DFS.

(a)

(b)

(c)